Compass Therapeutics Says FDA Wants New Survival Trial Before Tovecimig BLA

What happened

Compass Therapeutics, a small clinical-stage biotech that develops antibody-based cancer drugs, said the U.S. Food and Drug Administration recommended it run an additional trial showing a survival benefit before it submits a Biologics License Application for its drug tovecimig in biliary tract cancer, according to the company's regulatory update and coverage by BioSpace, StockTitan and medpath.

The company said it disagrees that a new trial is warranted, pointing to data from its Phase 2/3 COMPANION-002 study, which it says includes a statistically significant result. Compass said it will continue discussing the matter with the FDA while it keeps preparing its BLA submission.

Shares closed at $1.135, down 2.99% from the prior close of $1.17, according to the price data. The larger double-digit percentage drop reported in social media posts around the event is not reflected in those closing figures.

The dispute

The disagreement is about what evidence the FDA will accept. The agency's position, as Compass describes it, is that a survival trial is needed before a BLA can be filed for tovecimig in biliary tract cancer. Compass's position is that the COMPANION-002 data already supports filing.

Compass has not said it will stop preparing the application. Its stated plan is further discussions with the FDA while the BLA work continues, according to the company's update and BioSpace's report.

Note what the sources do and do not establish. They establish the FDA's recommendation, Compass's disagreement and its plan to keep talking to the agency. They do not establish the FDA's reasoning beyond the recommendation itself, and they do not establish a timeline for a resolution.

What this means

A Biologics License Application, or BLA, is the formal request a company files with the FDA for permission to sell a biologic drug in the United States. Until the FDA accepts and approves one, a drug cannot be marketed. The FDA can decline to accept a filing, or, as here, tell a company before filing that it wants more data first.

Tovecimig is Compass's drug candidate in biliary tract cancer, a cancer of the bile ducts and gallbladder. The COMPANION-002 study was a Phase 2/3 trial, meaning a mid-to-late stage study designed to test whether the drug works and to support a marketing application.

The sticking point is overall survival, often shortened to OS. That is how long patients live, measured from a set point. A result is "statistically significant" when it is unlikely to be due to chance alone. The reported dispute is about whether COMPANION-002 produced the kind of survival evidence the FDA wants for this cancer, where treatment options are limited.

A company in this position typically responds by requesting a meeting with the FDA to argue its case, generating more data, or running the requested trial. Which path Compass takes is not yet determined by the sources available; the company has only said it will keep discussing the matter and preparing its application. Any of those paths takes time and money, which matters for a company with no approved product and no product revenue.